Corrigendum to “Multifunctional all-in-one drug delivery systems for tumor targeting and sequential release of three different anti-tumor drugs” [Biomaterials 76C (2015) 399–407] (S0142961215008790)(10.1016/j.biomaterials.2015.10.069);Multifunctional all-in-one drug delivery systems for tumor targeting and sequential release of three different anti-tumor drugs

Biomaterials

Volumn 76, Issue , 2016, Pages 399-407

  Fan, Li ^a,b   Zhang, Yongsheng ^c   Wang, Fuli ^d   Yang, Qian ^a   Tan, Jiali ^e   Renata, Grifantini ^f   Wu, Hong ^a   Song, Chaojun ^a   Jin, Boquan ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^d FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^e SUN YAT SEN UNIVERSITY   (China)

^f Externautics SpA   (Italy)

Author keywords

Bcl 2; Dox; HCPT; Self decomposable nanoparticles; Sequential drug release

Indexed keywords

ANTIBODIES; DRUG PRODUCTS; GOLD; MONOCLONAL ANTIBODIES; NANOPARTICLES; TUMORS;

3-AMINOPROPYLTRIETHOXYSILANE; BCL-2; DRUG DELIVERY SYSTEM; DRUG RELEASE; HCPT; NANOPARTICULATE SYSTEM; SUSTAINABLE RELEASE; SYSTEMIC TOXICITIES;

CONTROLLED DRUG DELIVERY;

10 HYDROXYCAMPTOTHECIN; DOXORUBICIN; GOLD NANOPARTICLE; MONOCLONAL ANTIBODY; PROTEIN BCL 2; SILICA NANOPARTICLE; SMALL INTERFERING RNA; SODIUM CHLORIDE; ANTINEOPLASTIC AGENT; BIOMATERIAL;

ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RELEASE; DRUG TARGETING; ENDOCYTOSIS; ENDOSOME; IN VITRO STUDY; IN VIVO STUDY; LYSOSOME; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NANOPHARMACEUTICS; NONHUMAN; PRIORITY JOURNAL; SEQUENTIAL DRUG RELEASE; STATIC ELECTRICITY; TUMOR VOLUME; DRUG DELIVERY SYSTEM; HUMAN; NEOPLASMS;

ANTINEOPLASTIC AGENTS; BIOCOMPATIBLE MATERIALS; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS;

EID: 84961211662     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2016.11.002     Document Type: Erratum

References (23)

1. Amin K.B.S.M.L. Nanotechnology in cancer drug delivery and selective targeting. ISRN Nanotechnol. 2014, 2014.
2. Torchilin V. Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. Eur. J. Pharm. Biopharm. Off. J. Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV 2009, 71:431-444.
3. Torchilin V.P. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat. Rev. Drug Discov. 2014, 13:813-827.
4. Harris J.M., Chess R.B. Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov. 2003, 2:214-221.
5. Niidome T. 9. Diagnostic and therapeutic applications of biocompatible gold nanorods: original research article: PEG-modified gold nanorods with a stealth character for in vivo applications, 2006. J. Control. Release Off. J. Control. Release Soc. 2014, 190:48-50.
6. Gao J., Zhong W., He J., Li H., Zhang H., Zhou G., et al. Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes. Int. J. Pharm. 2009, 374:145-152.
7. Tsouris V., Joo M.K., Kim S.H., Kwon I.C., Won Y.Y. Nano carriers that enable co-delivery of chemotherapy and RNAi agents for treatment of drug-resistant cancers. Biotechnol. Adv. 2014, 32:1037-1050.
8. Zhang L., Lu Z., Zhao Q., Huang J., Shen H., Zhang Z. Enhanced chemotherapy efficacy by sequential delivery of siRNA and anticancer drugs using PEI-grafted graphene oxide. Small 2011, 7:460-464.
9. Tekedereli I., Alpay S.N., Akar U., Yuca E., Ayugo-Rodriguez C., Han H.D., et al. Therapeutic silencing of Bcl-2 by systemically administered siRNA nanotherapeutics inhibits tumor growth by autophagy and apoptosis and enhances the efficacy of chemotherapy in orthotopic xenograft models of ER (-) and ER (+) BREAST cancer. Mol. Ther. Nucleic Acids 2013, 2:e121.
10. Yoon H.Y., Son S., Lee S.J., You D.G., Yhee J.Y., Park J.H., et al. Glycol chitosan nanoparticles as specialized cancer therapeutic vehicles: sequential delivery of doxorubicin and Bcl-2 siRNA. Sci. Rep. 2014, 4:6878.
11. Zhang Y., Xiao C., Li M., Chen J., Ding J., He C., et al. Co-delivery of 10-hydroxycamptothecin with doxorubicin conjugated prodrugs for enhanced anticancer efficacy. Macromol. Biosci. 2013, 13:584-594.
12. Liao L., Liu J., Dreaden E.C., Morton S.W., Shopsowitz K.E., Hammond P.T., et al. A convergent synthetic platform for single-nanoparticle combination cancer therapy: ratiometric loading and controlled release of cisplatin, doxorubicin, and camptothecin. J. Am. Chem. Soc. 2014, 136:5896-5899.
13. FAN L., Jin B., Zhang S., Song C., Li Q. Stimuli-free programmable drug release for combination chemo-therapy. Nanoscale 2015, in press. 10.1039/C5NR06305A.
14. Fan L., Campagnoli S., Wu H., Grandi A., Parri M., De Camilli E., et al. Negatively charged AuNP modified with monoclonal antibody against novel tumor antigen FAT1 for tumor targeting. J. Exp. Clin. Cancer Res. CR 2015, 34:103.
15. Hu J., Liu G., Wang C., Liu T., Zhang G., Liu S. Spatiotemporal monitoring endocytic and cytosolic pH gradients with endosomal escaping pH-responsive micellar nanocarriers. Biomacromolecules 2014, 15:4293-4301.
16. Greish K. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. Methods Mol. Biol. 2010, 624:25-37.
17. Hong R., Han G., Fernandez J.M., Kim B.J., Forbes N.S., Rotello V.M. Glutathione-mediated delivery and release using monolayer protected nanoparticle carriers. J. Am. Chem. Soc. 2006, 128:1078-1079.
18. Li Y., Zaluzhna O., Xu B., Gao Y., Modest J.M., Tong Y.J. Mechanistic insights into the Brust-Schiffrin two-phase synthesis of organo-chalcogenate-protected metal nanoparticles. J. Am. Chem. Soc. 2011, 133:2092-2095.
19. Juliano R., Alam M.R., Dixit V., Kang H. Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res. 2008, 36:4158-4171.
20. Li T., Wu M., Zhu Y.Y., Chen J., Chen L. Development of RNA interference-based therapeutics and application of multi-target small interfering RNAs. Nucleic Acid. Ther. 2014, 24:302-312.
21. Gujrati M., Malamas A., Shin T., Jin E., Sun Y., Lu Z.R. Multifunctional cationic lipid-based nanoparticles facilitate endosomal escape and reduction-triggered cytosolic siRNA release. Mol. Pharm. 2014, 11:2734-2744.
22. Kreft M., Milisav I., Potokar M., Zorec R. Automated high through-put colocalization analysis of multichannel confocal images. Comput. Methods Programs Biomed. 2004, 74:63-67.
23. Wu G, Song C, Renata G, Fan L, Wu H, Jin B. Supporting data for multifunctional all-in-one drug delivery systems for tumor targeting and sequential release of three different anti-tumor drugs. Data Brief; (Submitted).